NCT03516045

A Study of 18F-AlF-NOTA-Neurotensin PET/CT for Imaging Prostate Cancer

• Status: Unknown
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 65 (estimated)
• Sponsor: Xiangya Hospital of Central South University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The aim of this study is to investigate the clinical value of \[18F\]aluminum fluoride-1,4,7-triazacyclononane-1,4,7-triacetic acid-neurotensin（18F-AlF-NOTA-neurotensin）positron emission tomography / computed tomography (PET/CT) in patients with prostate cancer (PCa).

Detailed description

18F-AlF-NOTA-neurotensin is a radioligand targeting the neurotensinreceptor, which is widely expressed on the cell surface of PCa. The radioligand can be used for the diagnosis and stage of the PCa. A total of 5 volunteers and 60 PCa patients will be subjected to a 18F-AlF-NOTA-neurotensin PET/CT scan. The uptake of 18F-AlF-NOTA-neurotensin in organs and tumor lesions will be quantified as Standardized Uptake Values (SUVmax/SUVmean).

Conditions

• Prostate Cancer

Interventions

Type	Name	Description
DRUG	18F-AlF-NOTA-neurotensin	One injection of the radioligand 18F-AlF-NOTA-neurotensin

Timeline

• Start date: 2018-04-23
• Primary completion: 2019-12-30
• Completion: 2020-12-30
• First posted: 2018-05-04
• Last updated: 2018-05-17

Locations

1 site across 1 country: China